Novavax, Inc. - Common Stock (NQ:NVAX)

10.46 -0.14 (-1.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

68 69 Next >

US Stocks Likely To Open In Red After Jerome Powell Says No Need To Be 'In A Hurry' On Rate Cuts: Tesla, TSMC And Domino's In Focus ↗

November 15, 2024

U.S. stocks could open on a negative note on Friday after the Federal Reserve chair Jerome Powell's comments on Thursday that the economy is showing enough strength that there is no need to be "in a...

Via Benzinga

Topics Economy

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗

November 14, 2024

Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.

Via Benzinga

Topics Government

Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls ↗

November 12, 2024

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered.

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Outlook For Novavax ↗

November 11, 2024

Via Benzinga

Looking Into Novavax's Recent Short Interest ↗

November 11, 2024

Via Benzinga

How Is The Market Feeling About Novavax? ↗

November 06, 2024

Via Benzinga

Here's How Much $1000 Invested In Novavax 5 Years Ago Would Be Worth Today ↗

October 02, 2024

Via Benzinga

Looking Into Novavax's Recent Short Interest ↗

October 01, 2024

Via Benzinga

FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial ↗

November 11, 2024

FDA lifts clinical hold on Novavax's COVID-19-influenza combo vaccine, clearing path for Phase 3 trials. Novavax to resume trial activities soon.

Via Benzinga

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday? ↗

November 06, 2024

Novavax ends UK COVID-19 vaccine contract, agreeing to repay $123.8M in quarterly installments by 2027 as part of settlement.

Via Benzinga

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

October 28, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today ↗

September 17, 2024

Via Benzinga

3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment ↗

October 26, 2024

Knowing these will help you avoid making suboptimal investing decisions.

Via The Motley Fool

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? ↗

October 21, 2024

Let's look beyond this piece of bad news from regulators.

Via The Motley Fool

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm

October 20, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

How Bad Is This News for Novavax? ↗

October 19, 2024

Novavax stock fell 20% in one trading session on the news.

Via The Motley Fool

Robinhood, Novavax, Phunware, Lucid Group, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 16, 2024

On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.

Via Benzinga

Topics Stocks

Nasdaq Moves Higher; Morgan Stanley Profit Beats Estimates ↗

October 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 16, 2024

Via Benzinga

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗

October 16, 2024

Via Benzinga

Topics Stocks

FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves ↗

October 16, 2024

Novavax stock dips as the FDA pauses its COVID-19-influenza vaccine trials following a serious adverse event.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 16, 2024

Via Benzinga

What's Going On With Novavax Stock Today? ↗

October 09, 2024

Novavax Inc (NASDAQ:NVAX) shares are bouncing around Wednesday, pulling back after popping in early trading. The company announced that it received European marketing authorization for its Nuvaxovid...

Via Benzinga

RPM International Posts Upbeat Earnings, Joins Joby Aviation, Ciena And Other Big Stocks Moving Higher On Wednesday ↗

October 02, 2024

Via Benzinga

Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗

October 01, 2024

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Via Talk Markets

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions ↗

September 16, 2024

Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...

Via Benzinga

Should You Buy Novavax Stock After This Regulatory Win? ↗

September 13, 2024

The biotech continues to earn important wins, but is it enough?

Via The Motley Fool

Why Are Novavax Shares Trading Lower Today? ↗

September 12, 2024

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.